high mobility group box 3 pseudogene 9Genealiases: []
Q-omics provides the consensus-scored HMGB3P9 profile across patient tissues and cancer cell-line models. HMGB3P9 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, HMGB3P9 is differentially expressed in 3, with the highest sampling consensus in PAAD. Additionally, HMGB3P9 RNA expression shows 10,237 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight PAAD, and THYM as cancer lineages where HMGB3P9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HMGB3P9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HMGB3P9 survival associations across molecular data types. HMGB3P9 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HMGB3P9 RNA expression–survival associations across cancer types. High HMGB3P9 expression shows unfavorable associations in PAAD, KICH, KIRC, UCEC, READ and COAD. The PAAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify PAAD as the clearest survival context for HMGB3P9 RNA expression.
This table summarizes HMGB3P9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for HMGB3P9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HMGB3P9 shows lower tumor expression in THCA and higher tumor expression in PAAD and BLCA. The PAAD box plot shows higher HMGB3P9 RNA expression in tumor versus normal tissue (log2 FC = +0.380, t-test p = .038).
This table shows molecular features associated with HMGB3P9 in patient tissues and cancer cell lines. In patient samples, HMGB3P9 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
